TALIS BIOMEDICAL CORP (TLIS)
US87424L2079 - Common Stock
TLIS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Health Care Equipment & Supplies industry. While TLIS has a great health rating, there are worries on its profitability. While showing a medium growth rate, TLIS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TLIS had negative earnings in the past year.
In the past year TLIS has reported a negative cash flow from operations.
TLIS had negative earnings in 4 of the past 5 years.
In the past 5 years TLIS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -65.49%, TLIS is doing worse than 77.72% of the companies in the same industry.
TLIS has a worse Return On Equity (-89.71%) than 64.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.49% | ||
| ROE | -89.71% | ||
| ROIC | N/A |
ROA(3y)-68.17%
ROA(5y)-29.56%
ROE(3y)-86.99%
ROE(5y)-37.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TLIS (97.94%) is better than 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for TLIS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLIS has more shares outstanding
Compared to 5 years ago, TLIS has more shares outstanding
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TLIS has an Altman-Z score of -8.93. This is a bad value and indicates that TLIS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLIS (-8.93) is worse than 77.20% of its industry peers.
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.93 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
TLIS has a Current Ratio of 8.86. This indicates that TLIS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.86, TLIS belongs to the best of the industry, outperforming 88.08% of the companies in the same industry.
TLIS has a Quick Ratio of 8.86. This indicates that TLIS is financially healthy and has no problem in meeting its short term obligations.
TLIS has a Quick ratio of 8.86. This is amongst the best in the industry. TLIS outperforms 91.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.86 | ||
| Quick Ratio | 8.86 |
3. Growth
3.1 Past
TLIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.20%, which is quite impressive.
TLIS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.71%.
TLIS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.24% yearly.
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50.83%
Revenue 1Y (TTM)-55.71%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Revenue growth Q2Q-25%
3.2 Future
The Earnings Per Share is expected to grow by 6.67% on average over the next years.
TLIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 154.95% yearly.
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TLIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
TLIS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TALIS BIOMEDICAL CORP
NASDAQ:TLIS (5/17/2024, 7:00:01 PM)
8.98
-0.18 (-1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.49% | ||
| ROE | -89.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.86 | ||
| Quick Ratio | 8.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y27.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-55.71%
Revenue growth 3Y-42%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y